Intelligence Framework
NORSINCOM monitors six primary risk categories that drive pharmaceutical supply chain disruption.
Facility shutdowns, production halts, regulatory suspensions, and force majeure events at API or finished-dose manufacturing sites.
Excessive dependence on a single country, region, or manufacturer for critical API supply — creating systemic vulnerability to localized disruptions.
FDA warning letters, GMP deviations, import alerts, contamination events, and recall actions that remove supply from the market.
Port congestion, shipping lane disruptions, export restrictions, and customs delays that interrupt the flow of pharmaceutical raw materials and finished goods.
Trade tensions, sanctions, conflict proximity, and diplomatic disruptions that affect pharmaceutical supply routes and manufacturing relationships.
Sudden demand spikes driven by disease outbreaks, pandemic declarations, or public health emergencies that overwhelm existing supply capacity.
Concentration Analysis
| Drug | Therapeutic Class | Primary API Source | Country | Concentration | Alt. Suppliers | Risk |
|---|---|---|---|---|---|---|
| Ciprofloxacin | Antibiotics | Aurobindo / Divi's Laboratories | India | 68% | 2 | CRITICAL |
| Metformin | Endocrinology | Multiple Indian Manufacturers | India | 74% | 3 | HIGH |
| Valsartan | Cardiovascular | Zhejiang Huahai / Hetero Drugs | China / India | 61% | 4 | HIGH |
| Carboplatin | Oncology | Fresenius Kabi / Cipla | Germany / India | 55% | 2 | HIGH |
| Insulin (Biosimilar API) | Endocrinology | Biocon / Wockhardt | India | 67% | 2 | CRITICAL |
| Amoxicillin | Antibiotics | CSPC Pharmaceutical | China | 42% | 6 | MEDIUM |
| Atorvastatin | Cardiovascular | Ranbaxy / Sun Pharma | India | 38% | 7 | LOW |
| Paracetamol (API) | Analgesics / OTC | Granules India / Anqiu Lu'an | India / China | 71% | 3 | HIGH |